Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_assertion type Assertion NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_head.
- NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_assertion description "[Primary screening with HC2 generally detects 23% (95% confidence interval, CI: 13-23%) more CIN-2, CIN-3, or cancer compared to cytology at cut-off atypical squamous cells of undetermined significance (ASCUS) or LSIL, but is 6% (95% CI: 4-8%) less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_provenance.
- NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_assertion evidence source_evidence_literature NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_provenance.
- NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_assertion SIO_000772 16950021 NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_provenance.
- NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_assertion wasDerivedFrom befree-20150227 NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_provenance.
- NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_assertion wasGeneratedBy ECO_0000203 NP651447.RAPVDE2iMd3UrPDW-wJXtUeX9uJyjhyCW216WYlEv4XEs130_provenance.